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412Intravenous Busulfan Plus Melphalan Is a Highly
Effective, Well-Tolerated Preparative Regimen for
Autologous Stem Cell Transplantation in Patients with
Advanced Lymphoid Malignancies
Partow Kebriaei,1 Timothy Madden,2 Reza Kazerooni,2 Xuemei Wang,3
Peter F. Thall,3 Celina Ledesma,1 Yago Nieto,1 Elizabeth J. Shpall,1 Chitra Hosing,1
Muzaffar Qazilbash,1 Uday Popat,1 Issa Khouri,1
Richard E. Champlin,1 Roy B. Jones,1 Borje S. Andersson1We investigated the administration of intravenous (i.v.) busulfan (Bu) combined with melphalan (Mel) in
patients with advanced lymphoid malignancies undergoing autologous stem cell transplantation. Bu 130
mg/m2 was infused daily for 4 days, either as a fixed dose per body surface area (BSA), or to target an average
daily area under the curve of 5000 mmol-min, determined by a test dose of i.v. Bu at 32 mg/m2 given 48 hours
prior to the high-dose regimen, followed by a rest day, followed by 2 daily doses of Mel at 70mg/m2. Stem cells
were infused the following day. Eighty patients had i.v. Bu delivered per test dose guidance. The median daily
systemic Bu exposure was 4867 mmol-min. One hundred two patients (Hodgkin lymphoma n 5 49, non-
Hodgkin lymphoma n 5 12, multiple myeloma 5 41) with a median age of 44 years (range: 19-65 years)
were treated. The 2-year overall survival and progression-free survival rates were 85% and 57%, respectively,
for patients with Hodgkin lymphoma, 67% and 64%, respectively, for patients with non-Hodgkin lymphoma,
and 82% and 42%, respectively, for patients with multiple myeloma. The regimen was very well tolerated with
treatment-related mortality at 100 days, 1 year, and 2 years of 1%, 3%, and 3%, respectively. Intravenous Bu-
Mel was well tolerated. Disease control wa encouraging, and should be explored in larger phase II studies.
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High-dose chemotherapy with autologous hemato-
poietic stem cell transplantation (SCT) is an accepted
treatment option for patients with advanced lymphoid
malignancies. Such therapy prolongs both progression-
free survival (PFS) and overall survival (OS) in patients
with chemotherapy-sensitive recurrent disease compared1Department of Stem Cell Transplantation and Cellular
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6/j.bbmt.2010.07.016with standard salvage chemotherapy. For patients with
chemotherapy-sensitive Hodgkin lymphoma (HL), free-
dom from treatment failure at 3 years was significantly
better following BEAM-SCT compared with Dexa-
BEAM and no transplant in a randomized study (55%
versus 34%, P5 .019) [1]. Similarly, significantly better
treatment outcomes following autologous SCT in pa-
tients with non-Hodgkin lymphoma (NHL), compared
with chemotherapy alone, were reported in the PARMA
study, with survival of 53%at 5 years [2].However, long-
term disease control is much less impressive after SCT in
patients with chemotherapy-refractory disease, with an
expected 10-year OS of only 10% to 20% following
SCT in patients with primary refractory HL [3,4] and
a 5-year OS of 10% in NHL patients [5,6]. Thus,
considerable success has been gained with autologous
SCT in patients with chemotherapy-sensitive recurrent
HL andNHL.However, these seeming advances, yield-
ing long-termdisease control in about half of the patients
with recurrent chemotherapy-sensitive diseaseonlyhigh-
light the need for further improvement of high-dose
Biol Blood Marrow Transplant 17:412-420, 2011 413Busulfan plus Melphalan for Autologous SCTregimens, such that an overall significant improvement
can be made for all patients categories; currently, none
of themost commonly used high-dose regimens provides
any significant benefit in patients with chemotherapy-
refractory disease [5,7-10].
In the efforts to develop more effective and less
toxic high-dose chemotherapy regimens, it has further
been assumed that alkylating agents, which form the
backbone of most pretransplant regimens, can ‘‘break
through’’ (limited) resistance to chemotherapy based
on their multiple intracellular mechanistic targets.
We also recognize that the systemic exposure of acti-
vated cyclophosphamide (Cy) is, at a minimum, very
difficult to standardize [11]. As an alternative, several
groups have evaluated the combination of busulfan
(Bu) and melphalan (Mel). Neither of these alkylators
needs to be activated, and they both display linear
pharmacokinetics in the dose range(s) to be utilized
[12-14]. Further, the good central nervous system
(CNS) penetration for both Bu and Mel [15] and their
relative nonoverlapping clinical toxicity profiles
should make this combination an effective, high-dose
chemotherapy regimen [16,17]. The Bu-Mel combina-
tion has been most utilized in multiple myeloma
(MM). Thus, the Spanish GETH and PETHEMA
groups reviewed the outcomes of MM patients receiv-
ing Mel 200 mg/m2, Mel 140 mg/m2 1 radiation, or
oral Bu 12 mg/kg 1 Mel 140 mg/m2 for autologous
SCT conditioning reported to the Spanish transplant
registry [18]. In this retrospective analysis, the Bu-
Mel combination yielded significantly better overall
response rates (97% versus 89% and 92%, P 5 .003),
although the 5-year OS of 47% was not significantly
improved [18]. Similarly, high complete remission
(CR) rates were observed following autologous SCT
with oral Bu and Mel conditioning in a multicenter
trial for patients with MM [19]. A recent update, how-
ever, documented a significant 5-year PFS advantage
for patients treated with a combination of intravenous
(i.v.) Bu and Mel compared with patients treated with
Mel alone (The European Group for Blood and Mar-
row Transplantation Conference Proceedings, March
2010). This was attributed primarily to the signifi-
cantly increased safety for patients who received i.v.
versus oral Bu in the combination.
The PETHEMA group noted higher rates of
hepatic veno-occlusive disease (VOD) in the patients
withMM treated with oral versus i.v. Bu as part of their
transplant conditioning regimen [20]. This confirmed
earlier observations of a decreased risk for VOD and
multiorgan failure in patients undergoing allogeneic
SCT for myeloid malignancies [21]. Furthermore,
once-daily i.v. Bu administration was noted to be safe
[22], and to have linear pharmacokinetics (PKs) with
highly reproducible intra- and interpatient systemic ex-
posure [14] and, finally, it allowed identification of an
optimized therapeutic interval represented by the Buarea under the plasma concentration-versus-time curve
(AUC) [23]. Based on these considerations, we hypoth-
esized that i.v. Bu given once daily for 4 days with PK-
guidance, followed by Mel given over 2 days, would
constitute a safe and highly efficacious salvage regimen
when delivered with autologous progenitor cell sup-
port. Here, we report the results of this combination
in patients undergoing autologous SCT for advanced
lymphoid malignancies. The results confirmed our
expectations and encourage further refinement of this
safe and highly cytoreductive regimen.PATIENTS AND METHODS
Patient Eligibility
The data were collected prospectively from pa-
tients treated from February 2005 to August 2008 on
a Phase 2, single-arm trial investigating the combina-
tion of i.v. Bu and Mel. The study was approved by
the institutional review board, and written informed
consent was obtained from all patients according to
institutional guidelines. Patients were eligible for this
study if they were between 18 and 65 years of age
with advanced lymphoid malignancies, specifically
MM, HL, and NHL beyond first complete remission
(CR1). Additional eligibility criteria included accept-
able renal and hepatic function with creatinine of
#1.5 mg% (clearance of $60 mL/min) and alanine
aminotransferase #3 times the upper normal limit,
a Zubrod performance status of 0 or 1, no evidence of
uncontrolled infection, and negative serology for hep-
atitis B, C, and HIV. Patients were required to have
adequate cardiac functiondemonstrated by left ventric-
ular ejection fraction $40%, and good lung function
demonstrated by forced expiratory volume in 1 second,
forced vital capacity, and diffusing capacity of lung for
CO2 corrected for hemoglobin of.50% of predicted.
Patients with active CNS disease were excluded.
Restaging studies were obtained within 30 days be-
fore SCT, and subsequently at 1 month, 3 months, and
6months followingSCT, and then every 6months for 3
years, and annually thereafter, as feasible. Staging
studies for patients with lymphoma included computed
tomography (CT) and positron-emission tomography
(PET) scans, and bone marrow (BM) biopsy when ap-
plicable; patients with MM had serum and urine elec-
trophoresis, immunofixation studies, free light chains,
BM biopsy and bone survey.Conditioning Regimen
The transplant conditioning regimen consisted of
i.v. Bu administered either as a fixed dose of 130 mg/
m2 infused over 3 hours once daily for 4 days or to
target an average daily AUC of 5000 mM-min 6
12%. In the latter scenario, the therapeutic dose was
414 Biol Blood Marrow Transplant 17:412-420, 2011P. Kebriaei et al.determined by a test dose of i.v. Bu administered at 32
mg/m2 and infused over 45 minutes approximately 48
hours before the first therapeutic Bu dose. The Bu ad-
ministrations were followed by a rest day to allow for
glutathione repletion, and Mel was administered at
a fixed dose of 70 mg/m2 infused over 30 minutes
once daily for 2 days. The autologous progenitor cells
were infused on the following day.
Peripheral Blood Progenitor Cell (PBPC)
Mobilization and Collection
The methods of PBPC mobilization, collection,
storage, and infusion have been described [24]. Patients
received nonpurged autologous PBPC collected after
mobilization with filgrastim alone (n 5 41) or filgras-
tim plus chemotherapy (n5 61) depending on the pro-
tocols for PBPC collection that were active at the time
of study entry. The target progenitor cell dose was 4
106 CD341 cells/kg with a minimal acceptable dose of
2  106 CD341 cells/kg. Patients who failed to reach
that target could undergo BM harvest at the discretion
of the treating physician. BMwas obtained by multiple
aspirations from the right and left iliac crest under gen-
eral anesthesia, with a target total nucleated cell dose of
3 108 cells/kg. All products were cryopreserved using
standard techniques.
Supportive Care
Phenytoin 600mg orally was used during and 1 day
after completion of i.v. Bu therapy, starting the evening
before the first dose [25]. Institutional transplant
guidelines for antimicrobial, antifungal, and antiviral
prophylaxis were followed. All patients received 5 mg/
kg filgrastim subcutaneously daily from day 11 until
their absolute neutrophil count (ANC) was .0.5
 109/L for 3 consecutive days. Packed red blood cells
were administered to maintain hemoglobin levels $8
g/dL. Platelet transfusions were administered to keep
platelet counts $10  109/L. All blood products were
filtered and irradiated.
Busulfan Pharmacokinetic/Therapeutic Drug
Monitoring
A total of 10 blood samples were collected for Bu
concentration determination during and up to about
14 hours following infusion of both the test dose and
first therapeutic dose of Bu. The target daily AUC
was 5000 6 12% mmol-min. If necessary, a second Bu
dose adjustment wasmade following the first therapeu-
tic dose analysis in efforts to keep the total course AUC
at 20,000 mmol-min. Blood for PK analyses was col-
lected from a peripheral line to avoid sample contami-
nation caused by the proximity between the different
central venous catheter ports. Samples were collected
in heparinized tubes and transported to the laboratory
on wet ice. Plasma was separated and analyzed withhigh-pressure liquid chromatography (HPLC) after
derivatization with diethyldithiocarbamate (DDTC)
[25], or during the latter phase of the study, by a newer
liquid chromatography-mass spectrometry (LC-MS)
technique, which significantly shortens processing
and sample run times, but with retained sensitivity
and accuracy [26] (Timothy Madden, personal com-
munication). All concentration-time plasma Bu data
were analyzed using an open 1-compartment PK
model, using the ADAPT II software program, version
4.0 (Biomedical Simulation Resource, University of
Southern California, Los Angeles, CA) [14,27].Definitions and Clinical Outcome Variables
Standardized disease response criteria were used
for disease staging and response to transplant in HL
andNHL patients [28]. A CRwas defined as the disap-
pearance of all measurable lesions for .30 days. A re-
sidual PET negative mass in a previously PET
positive patient was counted as CR. Partial remission
(PR) was defined as a .50% decrease in measurable
disease without the appearance of new lesions, stable
disease (SD) was defined as a\50% decrease in mea-
surable disease without the appearance of new lesions,
and progressive disease (PD) was defined as a .25%
increase in measurable disease or the appearance of
a new lesion. For patients with MM, CR was defined
as the disappearance of the monoclonal protein on
immunofixation analysis. A PR was defined as a reduc-
tion of .50% in serum paraprotein levels and/or a re-
duction of .90% in urinary paraprotein levels for at
least 6weeks. For patients with nonsecretoryMM, a re-
duction of .50% in BM plasma cells was considered
indicative of a PR, whereas the observation of\5%
BM plasma cells was considered indicative of a CR.
Disease progression was defined by an increase of
.25% in serumor urinary paraprotein levels on at least
2 occasions, an increase in the number or size of osteo-
lytic lesions, or the development of hypercalcemia [29].
For all disease types, patientswho achieved at least a PR
with salvage chemotherapy administered before trans-
plantation were considered to have chemotherapy-
sensitive disease and patients who had less than a PR
were classified as chemotherapy-resistant.
Hematologic recovery was defined on the date that
the patient had an absolute neutrophil count $0.5
 109/L for 3 consecutive days. Platelet recovery was
defined as occurring on the first of 7 consecutive
days with a platelet count$20  109/L without trans-
fusion support. Failure to engraft by day130 was con-
sidered primary engraftment failure. OSwas defined as
the time from the date of transplant until date of death
from any cause, and patients still alive at last follow-up
were considered censored. PFS was defined as the date
of transplantation until date of progression or death
from any cause. Treatment-related mortality was
Table 1. Patient Characteristics at Diagnosis
Characteristic No. Patients
Total patients 102
Sex, female/male 38/64
Disease histology at diagnosis
Hodgkin lymphoma
Nodular sclerosis 43
Mixed cellularity 4
Lymphocyte deplete 1
Nodular lymphocyte predominant 1
Non-Hodgkin lymphoma
Diffuse large cell 6
Follicular, large cell 1
Follicular, mixed small and large cell 3
Anaplastic 1
Mantle cell 1
Multiple Myeloma
IgG 23
IgA 9
IgM plasma cell leukemia 1
Nonsecretory 2
Light chain only 6
Disease stage at diagnosis
Hodgkin or non-Hodgkin lymphoma
I 2
II 21
III 18
IV 17
Unknown 3
Multiple myeloma
Durie-Salmon I 9
Durie-Salmon II 15
Durie-Salmon III 17
LDH
Elevated 9
Biol Blood Marrow Transplant 17:412-420, 2011 415Busulfan plus Melphalan for Autologous SCTdefined as death from any cause other than disease
progression or relapse. Toxicity was scored using the
modifiedNational Cancer Institute CommonToxicity
Criteria version 3.0 (NCI, Bethesda, MD).
Adverse events and hematologic parameters were
monitored daily and clinical chemistry parameters at
least twice weekly during the initial hospitalization pe-
riod. Subsequently, patients were followed up at least
quarterly during the first year with physical examina-
tions, blood counts, and CT and/or PET scans, BM as-
piration, and biopsy as clinically indicated.
Statistical Methods
Theprimaryoutcomes for this single-arm trialwere
safety and OS. Patients were categorized by disease
type, with safety monitoring performed separately
within each disease subtype based on accruing survival
time data. Bayesian early stopping rules based on the
observed rates of these 2 outcomes, compared to histor-
ical data, were implemented separately for each disease
subtype [30]. The Kaplan-Meier estimator [31] was
used to assess OS and PFS probabilities in months.
Descriptive statistics were used to summarize patient
demographics. Three patients withMM received a sec-
ond transplant in stable disease that was not part of the
originally planned treatment program; these 3 patients
were censored at the time of their second SCT.Unknown 66
B2 microglobulin
Elevated 31
Unknown 57
B symptoms in NHL, HL
Present 32
Unkown 7
Bulky disease in NHL, HL
Yes 23
Unknown 24
LDH indicates lactate dehydrogenase; NHL, non-hodgkin lymphoma;
HL, hodgkin lymphoma.RESULTS
Patient and Treatment Characteristics
Patient demographics and baseline disease charac-
teristics are listed in Tables 1 and 2. One hundred two
patients (49HL, 12NHL, 41MM) withmedian age of
44 years (range: 19–65 years) were evaluated on this
study. The median number of prior treatment
regimens was 3 (range: 1-6), with 2 MM patients
having had a prior auto-SCT. The majority of patients
had advanced disease at time of transplant; only 13%
(n 5 13) were in clinical remission, whereas 87%
(n5 89) had active disease. Among those transplanted
with active disease, 21% were documented as
chemotherapy-refractory. Eighty patients (78%) had
PK-directed Bu dosing.
Graft Content and Engraftment
Stem cell graft characteristics and hematopoietic
recovery data are summarized in Table 2. The source
of stem cells was peripheral blood for the majority of
patients. The median total nucleated cell (TNC)
count and CD341 cell doses were 6.8 108/kg (range:
1.56-33.9) and 5.26  106/kg (range: 2.49-12.49),
respectively. The median time to neutrophil and plate-
let recovery were 10 (range: 8-13) and 9 days (range:
7-31), respectively.Four patients received BM infusions after PBPC
mobilization was unsuccessful. The TNC recovery
from the BM product was marginal in 3 of the 4 pa-
tients with median TNC count and CD341 cell doses
1.9  108/kg (range: 1.69-4.67) and 0.9  106/kg
(range: 0.72-1.21), respectively. All 4 patients had de-
layed engraftment, with an average 47 days to neutro-
phil recovery; only 1 patient recovered platelets at 141
days. Three patients were rescued with allogeneic
SCT; 1 patient died with rapidly progressive disease
while awaiting an allogeneic SCT.OS
Among 49 patients with HL, 38 were alive at a me-
dian follow-up of 34 months (range: 4-51) with 1- and
2-year OS rates of 90% and 85%, respectively
(Figure 1). Among 12 patients with NHL, 8 were alive
at a median follow-up of 35 months (range: 4-53) with
Table 2. Patient, Graft Characteristics at Transplant, and
Hematopoietic Recovery
Characteristic No. Patients
Total patients 102
Median age at transplant (range) 44 (19-65) years
Hodgkin and non-Hodgkin 61
Median months to SCT (range) 18 (8-140)
Median lines prior therapy (range) 3 (1-6)
Disease status at transplant
Complete remission 2 13
Sensitive relapse 36
Refractory relapse 12
Multiple myeloma 41
Median months to SCT (range) 8 (3-116)
Median lines prior therapy (range)* 2 (1-6)
Disease status at transplant
Persistent disease, chemosensitive 34
Persistent disease, chemorefractory 7
Stem cell source
Bone marrow 4
Peripheral blood 98
Graft composition, median (range)
Total nucleated cells (108/kg) 6.5 (1.6-33.9)
CD34+ (106/kg) 5.2 (0.7-12.5)
Days to ANC >0.5  109/L, median (range) 10 (8-44)
Days to platelet >20  109/L, median (range) 9 (7-141)
SCT indicates stem cell transplantation; ANC, absolute neutrophil
count.
*2 Prior autologous SCTs.
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(Figure 2). Among 41 MM patients, 30 were alive at
a median follow-up of 38 months (range: 3-57), with
1- and 2-year OS rates of 91% and 82%, respectively
(Figure 3). Sensitivity to chemotherapy did not have
a significant impact on OS in any of the disease types
(Figures 1-3).
Response, Relapse, and PFS
Among 49 patients with HL, 34 achieved a com-
plete (CR) response and 11 achieved a partial response
(PR) for an overall response rate of 92%.Twenty-three
patients relapsed, with 1- and 2-year PFS rates of 63%
and 57%, respectively (Figure 1). Among 12 patientsTime (months)
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Figure 1. Overall survival (OS) and progression-free survival (PFS) for patien
icantly affect outcome.with NHL, 6 achieved a CR and 3 achieved a PR for
an overall response rate of 75%. Five patients relapsed,
with 1- and 2-year PFS rates stable at 64% (Figure 2).
Among 41 MM patients, 7 achieved a CR and 16
achieved a PR for an overall response rate of 58%.
Twenty-five patients relapsed, with 1- and 2-year
PFS rates of 67% and 42%, respectively (Figure 3).
Sensitivity to chemotherapy did not significantly im-
pact PFS in any of the disease types (Figures 1-3).
Treatment Toxicity
Regimen-related toxicities (RRTs) are detailed in
Table 3. No grade IV toxicity was noted. The most
commonly observed toxicities were grade I or II nausea
and vomiting (77%), mucositis (67%), and diarrhea
(55%). Grade I or II reversible elevation of liver func-
tion tests occurred in approximately 23% of patients;
grade III liver enzyme toxicity was noted in 4% of
patients. Only 1 case of mild-to-moderate VOD was
ascertained using Jones’ criteria [32]. This was a 42-
year-old patient who had received 2 lines of chemo-
therapy (ABVD, ESHAP) for refractory Hodgkin
disease prior to transplant; VOD developed approxi-
mately 1 month after SCT and resolved with sup-
portive measures. Significant CNS toxicity was not
observed, but 1 patient who was unable to take his pro-
phylactic phenytoin because of nausea and vomiting
suffered a seizure. There were 3 cases of grade I
pulmonary toxicity manifested as mild shortness of
breath, and 6 cases of possible grade II pulmonary tox-
icity manifested as pulmonary infiltrates and shortness
of breath without isolation of definite infectious
causes; this symptomatology resolved with inhaled or
oral steroid therapy; 5 of these cases were HL patients
who had received bleomycin therapy, and additionally
1 of the HL patients had received therapeutic medias-
tinal radiation therapy, and 1 was an MM patient who
had received a prior autologous SCT. The cumulative
incidences of treatment-related mortality (TRM) atTime (months)
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Figure 2. OS and PFS for patients with non-Hodgkin lymphoma. Sensitivity to chemotherapy does not have a significant impact on outcome.
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spectively. There were a total 3 nonrelapse deaths, all
related to infection. One death resulted following
complications from an allogeneic SCT, which was re-
quired after a patient with NHL developed therapy-
related myelodysplastic syndrome within 100 days fol-
lowing the autologous transplant.
PK Studies
BuPKparameters were calculated from the data ob-
tained from blood samples of 80 consenting patients.
The drug is known to be cleared in less than 24 hoursTime (months)
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Figure 3. OS and PFS for patients with multiple myeloma (MM). Senwithout drug accumulation observed over the 4-day
dosing interval. Over 85%of patients had interdose var-
iation of calculated clearance (ClT) estimates of\20%
between the test dose and first therapeutic dose; with
overall mean difference of calculated test-to-
therapeutic ClT of 5.0% (612.7%) for all patients.
The mean (CV%) population ClT, volume of distribu-
tion (Vd), and plasmahalf-life (t1/2) for once-daily dosing
were 97.9 ml/min/m2 (15.7%), 22.9 L/m2 (14.0%), and
2.7 hours (15.0%) from the first therapeutic dose. The
mean andmedian daily AUCs from the first therapeutic
dose were 4869 and 4867 mmol-min, respectively.Time (months)
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sitivity to chemotherapy does not significantly affect outcome.
Table 3. Regimen-Related Toxicity in 102 Patients
Grade, n (%)
Toxicity Grade I Grade II Grade III Grade IV
Liver
Transaminase elevation 6 (6) 0 (0) 1 (1) 0 (0)
Bilirubin elevation 6 (6) 5 (5) 2 (2) 0 (0)
VOD 0 (0) 0 (0) 1 (1) 0 (0)
Alkaline phosphatase elevation 6 (6) 0 (0) 1 (1) 0 (0)
Gastrointestinal tract
Diarrhea 37 (36) 19 (19) 5 (5) 0 (0)
Nausea and vomiting 49 (48) 30 (29) 7 (7) 0 (0)
Mucositis 18 (18) 50 (49) 7 (7) 0 (00)
Urinary tract/kidney
Creatinine elevation 2 (2) 0 (0) 0 (0) 0 (0)
Hemorrhagic cystitis 0 (0) 0 (0) 0 (0) 0 (0)
Skin
Rash 7 (7) 2 (2) 1 (1) 0 (0)
Neurologic
Seizures 0 (0) 1 (1) 0 (0) 0 (0)
Pulmonary/pleural
Shortness of breath 1 (1) 2 (2) 0 (0) 0 (0)
Pulmonary infiltrate 2 (2) 5 (5) 0 (0) 0 (0)
Cardiovascular
Tachycardia 1 (1) 0 (0) 3 (3) 0 (0)
VOD indicates veno-occlusive disease (of the liver).
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The robust antitumor activity of Bu and Mel has
been demonstrated in the autologous transplant setting
in children and adults with advanced myeloid and lym-
phoid malignancies[17,18,33,34]. All these earlier
studies used oral Bu, either in daily or divided doses;
severe mucositis and VOD were the most significant
toxicities reported. We hypothesized that i.v., PK-
guided Bu administration that allows for more precise
dose delivery with a tighter range in systemic drug
exposure would result in decreased RRT, improved
efficacy, and ultimately improved OS and PFS.
The disease control noted with this regimen ap-
pears at least equivalent with reported results from
similar alkylator-based combinations. The 2-year PFS
rate of 40% noted in patients with chemotherapy-
refractory HL compares favorably with previously
reported results with both chemotherapy-only and
TBI-based transplant regimens in similar high-risk
populations [3,4], albeit our findings are limited by
the small sample size. Similarly, the 2 patients with
chemotherapy-refractory NHL had a better PFS rate
compared to historic results [5,6], but a larger patient
cohort is needed to evaluate disease control in the
NHL population. We are continuing to explore this
combination in a subsequent trial where we have
added gemcitabine to the Bu-Mel combination, in an
attempt to utilize the previous experience with syn-
ergistic enhancement of cytotoxic effects when
combining nucleoside analogs and alkylating agents
[22,35-38]. Results from several other alkylating agent
combinations in various hematologic malignancies
suggest that the addition of a nucleoside analogmay be synergistic [9,35,37,39,40]. Thiotepa was
combined with Bu/Mel (BuMelTT) in patients with
NHL treated with auto-SCT in a study reported by
Zaucha et al. [9]. Patients treated with Bu/Mel/TT
had a significantly higher CR rate compared to patients
treated with BEAM in a retrospective analysis (56%
versus 31%, P 5 .03). Of importance, oral Bu was
used in this regimen, with 4 cases of liver failure noted
and a higher TRM rate compared to the BEAM group,
and ultimately no difference in OS [9].
Similarly, the outcomes noted with the Bu-Mel
combination in MM compare favorably with the stan-
dard Mel 200 mg/m2 transplant preparative regimen
used in MM. In a study of a single transplant with
Mel 200 conditioning in MM patients younger than
65 years, the CR rate was 44% and median survival
54.1 months [41]. We reported data from our center
withMel 200 mg/m2 for a single autologous transplant
that showed an overall response rate of 69% and me-
dian PFS of 20 months [42]. Intensification of this
transplant regimen has been attempted, with no addi-
tional benefit [42,43]. However, in a recent report, 55
patients received i.v. Bu at 3.2 mg/kg daily3 andMel
140 mg/2 daily 1 followed by autologous SCT. The
high overall response rate of 87% (CR 20%) and 1-
year PFS of 87% were impressive, although follow-
up is short at a median of 15 months [44]. These data
encouraged us to initiate a randomized study of Bu/
Mel compared with Mel alone at 200 mg/m2 to pro-
spectively compare these SCT conditioning regimens
in patients with myeloma.
In addition to good disease control, the 2-year
TRM rate of 3% in this study compares favorably to
rates reported for other myeloma and lymphoma
Biol Blood Marrow Transplant 17:412-420, 2011 419Busulfan plus Melphalan for Autologous SCTstudies. Only 1 case of reversible VOD was noted in
a heavily pretreated patient. Additionally, despite the
significant CNS penetration of both Bu andMel, a sei-
zure was noted in 1 patient who was unable to tolerate
the prophylactic oral phenytoin, underscoring the need
for seizure prophylaxis with this regimen. There were
no unexpected toxicities and prompt engraftment in
all patients receiving peripheral blood stem cell grafts.
Delayed count recovery and 1 case of graft failure was
noted only in the 4 patients receiving BM grafts after
peripheral blood stem cell yield was inadequate, sug-
gesting a fundamental weakness of the available pro-
genitor cell products. There were 6 cases of
(probable) pulmonary toxicity during the first 100
days following transplant in patients who had previ-
ously been heavily exposed to Bleomycin and/or chest
XRT. All of them responded promptly to steroid
therapy. No excess pulmonary toxicity was noted in
earlier studies utilizing either oral or i.v. Bu with Mel.
However, when oral Bu was combined with etoposide
and Cy, the 5-year incidence of pulmonary mortality
was noted to be 3.6%occurring at amedianof 5months
following transplant [45].
It may be likely that the use of i.v. Bu, which pro-
vides complete dose assurance and avoids the first-pass
hepatic effect, which contributes significantly to the
regimen’s impressive safety profile. The assumed ben-
efits from PK-directed Bu dosing were extrapolated
from our previous observations of an optimal thera-
peutic interval for Bu when used in the i.v. Bu/Cy2
regimen in patients receiving an allogeneic SCT for
chronic myelogenous leukemia [23]. In that report
the risk of RRT, acute graft-versus-host disease
(aGVHD), and death were analyzed as functions of
the per dose i.v. Bu AUC. Probabilities of developing
gastrointestinal toxicity, hepatotoxicity, mucositis,
and acute graft-versus-host disease were significantly
associated with elevated AUC. Most important, the
risk of death was significantly associated with AUC,
with risk significantly lower for patients receiving
a per-dose AUC between 950 and 1520 mmol-min
[23]. A similar trend was recently reported by Russell
and coworkers [36], who observed increased toxicity
when the average daily AUC exceeded 6000 mmol-
min in the 4-day Bu/Flu regimen. Extrapolating
from this data, the optimal daily Bu dose AUC would
be within the window of 3800 to 6080 mmol-min.
Thus, we targeted a (median) daily dose AUC of
5000 mmol-min for the present study. In a prior study,
we demonstrated that a daily Bu dose of 130 mg/m2
would be expected to yield a median daily AUC of ap-
proximately 4900 mmol-min [35]. Therefore, patients
who refused PK-directed Bu dosing received the fixed
daily Bu dose 130 mg/m2. The contribution of PK-
directed dosing to better overall outcome in this study
remains somewhat speculative, because the majority of
patients received PK-directed dosing, making itdifficult to discern any differences in those receiving
PK-guided versus fixed dose Bu with respect to toxicity
or disease control.
In conclusion, the results observed with the combi-
nation of i.v. Bu/Mel are encouraging in both MM and
lymphoma patients. Larger phase II studies are war-
ranted to further explore this combination.Additionally,
i.v., PK-directed Bu administration provides a safe,
controlled platform for introducing additional agents
to the combination to further augment disease control.ACKNOWLEDGMENTS
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